Here are four insights:
1. These drug increases are impacting both brand-name drugs and generics.
2. This price trend may be a consequence of drug research and development costs.
3. Others argue pharmaceutical companies are taking advantage of a “lack of bulk purchasing power.”
4. The Affordable Care Act is also not helping lowering drug prices.
More articles on quality & infection control:
Zika virus may be linked to eye damage in babies — 6 points
Zika virus impacts United Blood Services — 4 insights
Vascular surgery patients likely to quit smoking if offered personalized help from surgeons: 5 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
